BidaskClub lowered shares of Assembly Biosciences (NASDAQ:ASMB) from a strong-buy rating to a buy rating in a report issued on Wednesday.
Several other research firms have also recently weighed in on ASMB. Jefferies Group initiated coverage on shares of Assembly Biosciences in a report on Wednesday, November 8th. They issued a buy rating and a $50.00 price target on the stock. Zacks Investment Research cut shares of Assembly Biosciences from a hold rating to a sell rating in a report on Monday, August 14th. Finally, Chardan Capital reiterated a buy rating on shares of Assembly Biosciences in a report on Sunday, September 17th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of Buy and an average price target of $40.67.
Shares of Assembly Biosciences (ASMB) opened at $44.28 on Wednesday. Assembly Biosciences has a fifty-two week low of $11.07 and a fifty-two week high of $52.37.
In related news, Director William R. Ringo sold 1,000 shares of Assembly Biosciences stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $29.55, for a total value of $29,550.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In the last quarter, insiders sold 3,000 shares of company stock worth $112,620. 19.60% of the stock is currently owned by company insiders.
Hedge funds have recently made changes to their positions in the company. Nationwide Fund Advisors bought a new stake in shares of Assembly Biosciences during the 2nd quarter valued at $161,000. Renaissance Technologies LLC bought a new stake in shares of Assembly Biosciences during the 1st quarter valued at $242,000. Parametric Portfolio Associates LLC boosted its holdings in shares of Assembly Biosciences by 13.6% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 10,078 shares of the biopharmaceutical company’s stock valued at $208,000 after buying an additional 1,203 shares in the last quarter. Legal & General Group Plc bought a new stake in shares of Assembly Biosciences during the 2nd quarter valued at $212,000. Finally, Wells Fargo & Company MN bought a new stake in shares of Assembly Biosciences during the 2nd quarter valued at $213,000. Hedge funds and other institutional investors own 62.09% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Assembly Biosciences (ASMB) Cut to Buy at BidaskClub” was originally reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://ledgergazette.com/2017/12/10/assembly-biosciences-asmb-cut-to-buy-at-bidaskclub.html.
About Assembly Biosciences
Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.
Receive News & Ratings for Assembly Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.